Share Name Share Symbol Market Type Share ISIN Share Description
Alizyme LSE:AZM London Ordinary Share GB0000374289
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.08p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 8.17

Alizyme (AZM) Latest News

Real-Time news about Alizyme (London Stock Exchange): 0 recent articles
More Alizyme News
Alizyme Takeover Rumours

Alizyme (AZM) Share Charts

1 Year Alizyme Chart

1 Year Alizyme Chart

1 Month Alizyme Chart

1 Month Alizyme Chart

Intraday Alizyme Chart

Intraday Alizyme Chart

Alizyme (AZM) Discussions and Chat

Alizyme Forums and Chat

Date Time Title Posts
01/4/201620:56-- (Moderated) The NEW Official Alizyme Thread: The Next Phase --24,310.00
18/7/201207:26ALIZYME - THE TRACK RECORD SO FAR260.00
28/7/200911:48AZM Chart4.00
25/7/200909:57-- (Moderated) The NEW Official Alizyme Thread: STAYING ALIVE352.00
29/5/200811:24Let's Short This Duffer Out Of Business39.00

Add a New Thread

Alizyme (AZM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Alizyme trades in real-time

Alizyme (AZM) Top Chat Posts

DateSubject
24/7/2009
12:04
mad mike: alfiedduncan, I hope you are adding both the trades on LSE and on PLUS. If not you may be underestimating the shares trades by a very high amount. AZM trades on PLUS have been much greater than on the LSE, for quite sometime. For example as I type, 350K AZM shares trades on LSE, but 826K share trades on PLUS. Thus LSE trades only represent 29% of all AZM share trades today. FYI, you can put AZM on PLUS into your ADVFN monitor (I'm not sure if PLUS trades are reported real time or delayed on ADVFN)
10/7/2009
18:20
troutfish: I must join those once again having to correct VOWs comments and misrepresentations. CC and Optima have made it completely clear they are referring to a relist on AIM not the main market, as a possible option either very soon, or at the end of a period of Administration after Cetilistat Japan reports next year. A new quote on AIM costs £200,000 - £300,000, not £1 million like VOW says. Ongoing average costs of maintaing an AIM listing are £200,000 /year. This compares to ongoing costs of at least £300,000 - £400,000 /year for the main market. Typically companies on AIM have lower fees for nomads, auditors, lawyers and non-executive directors in view of lesser continuing obligations. Even if a Company delists completely from the Main Market and AIM there are secondary markets which allow trading on a matched bargain basis on which listing may cost very little (less than 10% of AIM). This (or AIM) could be an option although it might need a shareholder vote and there is no evidence of this in the AGM resolutions, just a hint of something in the Trading Update on 29/6/2009 about the main market listing: "The Company, with its advisers, is also considering the suitability of the Company's current main market listing given its market capitalisation and limited resources". I think any short-term move to reduce the listing costs would be welcomed, especially a move to AIM. P.S. Excellent posts from CC and Optima. ''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''' City Chappy - 10 Jul'09 - 09:03 - 158 of 162 A few thoughts. 1) If Alizyme go into Administration without significant debts the large shareholders might suggest to the Administrators the Company remains suspended in Administration until the Phase 3 Cetilistat Japan results are out next year or a deal is concluded sooner for ATL-104 (my assumption is the former, which would preserve more value for the Company and shareholders). Going into administration does not necessarily imply immediate liquidisation of assets! "An Administrators primary role is to rescue a Company as a going concern" - how true. If the Cetilistat results in 2010 are good the Company would receive a large milestone payment from Takeda and could then be requoted on AIM with the same number of shares as now, so preserving the holdings of all shareholders and giving big upside as the re-quoted price should be much higher. Further Cetilistat deals might then follow for other Asian and Pacific territories and the Company could progress ATL-104 through further trials. 2) Alternatively if current AGM resolutons 6 & 7 are approved, Alizyme might be able to place just enough shares to raise sufficient working capital (perhaps with any existing cash) to keep them quoted (probably on AIM and with minimal staff as now) until Cetilistat Japan reports next year or they can do a deal for ATL-104. Such a Placing would remove "going concern" fears and should result in a rise in the share price. 3) Even if the Company went into liquidisation, the assets of Cetilistat (e.g. Japan and maybe SE Asia) and ATL-104 appear to be worth more than the current market capitalisaton, so shareholders should get quite a lot back. (The share price is only now low because of "going concern" issues, not because the assets are are only worth the current share price). '''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''' Optima2 - 10 Jul'09 - 10:43 - 163 of 170 City Chappy good post. The large shareholders you mentioned in Point 1 also include outgoing CEO Tim McCarthy and his wife Susan (1,1080,000 shares) and directors like Sir Brian Richards. I think they would lobby any Administrators to hold off liquidisation and wait for the Cetilistat Japan results after next July which is not long, particularly as it is not unusual for companies to spend more than 12 months in Administration anyway. After then milestone cash from takeda should allow re-listing of Alizyme on AIM with the same number of shares as now and reappointment of Alan Goodman at the helm if he wanted the job. '''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''' Optima2 - 10 Jul'09 - 13:27 - 165 of 170 Obviously Administration involves delisting and i and CC did not imply otherwise. I just said the Administrators could re-list Alizyme [on AIM] after the Cetilistat Japan results in 2010 if it passed the trial because the Company would receive milestone cash from Takeda (even if delisted and in Administration) and subsequent sales royalties, making it a going concern again. You asked for examples of payouts to shareholders after Administration? - Shareholders often get payouts after Companies go into Administration and that is why some shareholders buy preference shares to increase their chances of such payouts. AZM do not have preference shares so all holders rank equally. - Ardana shareholders might get something back afterall even though it has taken 12 months: http://business.scotsman.com/businesstechnology/Ardana-39close-to-being-sold39.5364642.jp Use the same timeline for AZM and in 12 months (July 2010) Takeda will have completed Cetilistat Phase 3 in Japan and be about to release the pivotal Phase 3 results and potentially pay Alizyme a large milestone and future sales royalties. Administrators would have to take that into account together with opinions of shareholders (if offered) and any debtors on how to proceed. They might also decide they might out-license ATL-104 in the mean time and info posted here yesterday has shown that Amgen recently out-licensed Kepivance indicating there are partners out there for that type of drug. Remember the primary aim of Administrators is to keep a Company as a going concern. It is not to short-change shareholders or debtors, or to sell off the assets to the lowest bidder.
10/7/2009
09:43
optima2: City Chappy good post. The large shareholders you mentioned in Point 1 also include outgoing CEO Tim McCarthy and his wife Susan (1,1080,000 shares) and directors like Sir Brian Richards. I think they would lobby any Administrators to hold off liquidisation and wait for the Cetilistat Japan results after next July which is not long, particularly as it is not unusual for companies to spend more than 12 months in Administration anyway. After then milestone cash from takeda should allow re-listing of Alizyme on AIM with the same number of shares as now and reappointment of Alan Goodman at the helm if he wanted the job. ---------------------- City Chappy - 10 Jul'09 - 09:03 - 158 of 162 A few thoughts. 1) If Alizyme go into Administration without significant debts the large shareholders might suggest to the Administrators the Company remains suspended in Administration until the Phase 3 Cetilistat Japan results are out next year or a deal is concluded sooner for ATL-104 (my assumption is the former, which would preserve more value for the Company and shareholders). Going into administration does not necessarily imply immediate liquidisation of assets! "An Administrators primary role is to rescue a Company as a going concern" - how true. If the Cetilistat results in 2010 are good the Company would receive a large milestone payment from Takeda and could then be requoted on AIM with the same number of shares as now, so preserving the holdings of all shareholders and giving big upside as the re-quoted price should be much higher. Further Cetilistat deals might then follow for other Asian and Pacific territories and the Company could progress ATL-104 through further trials. 2) Alternatively if current AGM resolutons 6 & 7 are approved, Alizyme might be able to place just enough shares to raise sufficient working capital (perhaps with any existing cash) to keep them quoted (probably on AIM and with minimal staff as now) until Cetilistat Japan reports next year or they can do a deal for ATL-104. Such a Placing would remove "going concern" fears and should result in a rise in the share price. 3) Even if the Company went into liquidisation, the assets of Cetilistat (e.g. Japan and maybe SE Asia) and ATL-104 appear to be worth more than the current market capitalisaton, so shareholders should get quite a lot back. (The share price is only now low because of "going concern" issues, not because the assets are are only worth the current share price).
10/7/2009
08:03
city chappy: A few thoughts. 1) If Alizyme go into Administration without significant debts the large shareholders might suggest to the Administrators the Company remains suspended in Administration until the Phase 3 Cetilistat Japan results are out next year or a deal is concluded sooner for ATL-104 (my assumption is the former, which would preserve more value for the Company and shareholders). Going into administration does not necessarily imply immediate liquidisation of assets! "An Administrators primary role is to rescue a Company as a going concern" - how true. If the Cetilistat results in 2010 are good the Company would receive a large milestone payment from Takeda and could then be requoted on AIM with the same number of shares as now, so preserving the holdings of all shareholders and giving big upside as the re-quoted price should be much higher. Further Cetilistat deals might then follow for other Asian and Pacific territories and the Company could progress ATL-104 through further trials. 2) Alternatively if current AGM resolutons 6 & 7 are approved, Alizyme might be able to place just enough shares to raise sufficient working capital (perhaps with any existing cash) to keep them quoted (probably on AIM and with minimal staff as now) until Cetilistat Japan reports next year or they can do a deal for ATL-104. Such a Placing would remove "going concern" fears and should result in a rise in the share price. 3) Even if the Company went into liquidisation, the assets of Cetilistat (e.g. Japan and maybe SE Asia) and ATL-104 appear to be worth more than the current market capitalisaton, so shareholders should get quite a lot back. (The share price is only now low because of "going concern" issues, not because the assets are are only worth the current share price).
08/7/2009
12:47
vow: Qaz is in cut and paste mode. "south east asian and pacific teerritories" They have the combined value of less than one US state! AZM are made? It will have cost them £5m already this year, plus whatever funding required to get the £20m in milestones next year! Then they could receive $5-10m per annum in royalties on peak sales, not exactly made for life are they. This plus Colal payments, which look increasingly less likely, would have justified the share price at the current level of ownership, but the new funding will make this income alone unattractive imo. The US deal is the one, which should have been bringing in royalties of $20-25m per annum. You are better off just banging out the £20 share price predictions like you used to QAZ. I believe CEN was going to be £25 according to you before it dissappeared for next to nothing.
30/3/2009
11:50
peaeff: IFC I remember you and am sorry to see you with a 20% paper loss on further investment. I am sure that you are far more likel;y to recoup than myself and many others on the more recent ivestment but I have promised myself I shall buy no more. To answer your question, and IMO, the reasons for the share price being where it is at present are as follows. The mangement in it's present form have had over 2 years now and apart from uttering many helpings of spin, have done nothing to enhance either the position of, or the reputation of AZM. In fact one could argue that the opposite is true. The confidence of shareholders (barring one or two)is totally shot. If one is to believe what is posted by some shareholders there is no doubt that a lot of 'averaging down' has been done with each statement released by management and none of those statements has done any goos whatsoever to the share price. This has left many, no doubt, with heavy losses. To where do those punters turn now with cash wasting away and the future of this company in some doubt. The pipeline is now down to two products and we are in the lap of the gods as to whether either will produce any cash before time runs out. One could argue, as someone did this morning, that we could take comfort from the fact that the auditors have given the 'green light' for another year. Can we?, aren't those same auditors being advised by the same management team as us, as to what they are expecting in the next 12 months. HOW MANY TIMES HAVE THEY BEEN RIGHT in the past few years. How many times have they gotten the cash call wrong and issued more shares. Are they in a posotion to do that again?. Where is the interest coming from for Cetilistat. Other than Takeda what other name has been mentioned as a definate runner. The only hint we have had is that X out of Y major pharmas have shown, or are showing, an interest but, that, over the two years, the composition of X and Y may have changed albeit, we are told, through no fault of Cetilistat or management, but rather down to the internal problems of those X an Y companies. So what, whoever X and Y are, if they just don't want it because they consider the cost of marketing to be too much for the difference this would make to the marketplace. The milestone payments received for AZM products have probably not covered wages over the years and in my opinion have been so small as to suggest a 'take it or leave it' type negotiation. Was it not initially predicted that with Cetilistat, milestone payments of $45 dollars would be forthcoming. I thought the offering of entering stageIII was very poor compared with some deals that have gone ahead. So to sum up, lack of confidence in management, lack of confidence in the product and the general overall feeling that this will never be a big winner. They are my thoughs as a long term holder but, that is not to say that anyone wishing to invest at the present time, won't reap a good reward. Regards
30/3/2009
10:57
peaeff: Swan5 A little tentative there if I may say so. 'seems to mislead shareholders'. As far as I am concerned he has without any shadow of a doubt mislead shareholders and, I say that with confidence because, I am one of those he has mislead. Having made quite a serious loss by early 2007 I got out of AZM totally, crying 'enough is enough'. Then came the imfamous statement in October 2007 of deals before that year was out 'ACROSS THE BOARD'.(definition: applying equally to all) 'across the board' intimated to me that he would be doing deals on all products which, at that time, totalled FOUR, all of which had pleased in trials and two of which were referred to as blockbusters. I hoped that I could recover, at least, some of my losses so in I went again. Now that investment is 93% down and was made entirely on the back of that statement. Not only weren't the deals done 'across the board' but we have since lost two products, one, a so called 'blockbuster'. The two deals which were done will not have any material effect for some time, although hopefully before we run out of money, and because of their terms did more harm than good to the share price. To think that over 15 months later we are getting the same messages as back then is, IMO, why the share price is languishing at it's present level. Add to that the fact that our largest product of all (Ceti) has been accepted into phaseIII trials by it's only known supporter Takeda and, IMO, there is further ground for arguing that maybe we have been mislead about the quality of the product. TM has presided as CEO since Dr. PALMER left and it has been a rapid downhill trend ever since. Let us not forget either that PALMER managed to get around the 170p mark for his shares if I remember correctly. The reason for him going was rumoured to be, he couldn't get a deal because he was aiming too high. If one looks at today's price you would have to have a good laugh if that were true. His departure to me wreeks of other internal strife but was probably, in hindsight, most prophetic. Finally TM was asked at the recent webcast if our 'cash' position was having any effect on negotiations, and TM answered "no not at all". How can the man honestly believe that to be true. VOW - you post most days and critisize those who have a go at management, for whatever reason, and you continually seem to be trying to protect their image as though things here are no more than the norm and the fact that the share price has slumped from 200p to 6p is down to market forces. That frankly, IMO, is absolute b......ks. I just get the feeling that along the line you have managed, and if so all credit to you, to trade your way out of the bad position which many of us here have, unfortunately, gotten into. What you must accept is that you will not convince those people that they have not been mislead. To quote, as you do, failsafe paragraphs which are standard with most company's is not an argument and neither is the 'if you don't like it sell it' syndrome. I have to hold in the hope that there will be a turnaround of some kind but none of us can know just what form that will take, although I have consistently stated my belief that Takeda will play a big part in it and much of this delay has been stage managed on their behalf. Regards PF
16/3/2009
09:40
peaeff: VOW and all the other long sufferers. " They have always had a webcast with the results so I wouldn't read too much into that." In the past the webcasts have always represented a full house of products and the imminent hope of 'multi deals across the board' and, were viewed as the preferred vehicle for telling all the 'long suffering' shareholders just what the management team have achieved for them. The bare faced statements that have eminated from these events leaves one to wonder just how the hell we have arrived at a 5p shareprice today. The past year has been a total nightmare and it is difficult to percieve any outcome which will make any material difference or financial recovery for those of us who have been here long term. For the more recent investors 'good luck to you all'. So we have another webcast next Monday, what on earth, one wonders, could this 'George Washington', of the bio world, possibly have to say that we haven't heard before. More of the same would, surely, not be wasted on the media and, to my way of thinking, would be a total embarrassment to all concerned. Certainly it hasn't been arranged for the benefit of 'we' the shareholders because we are spoon fed by means of emails and phone calls in the hope we can drag some sort of morsel of comfort, or truth, from anything TM is likely to say. I would also hazard a guess that there have been no leaks as to what this webcast is about because that could have either destroyed the share price altogether or sent it scurrying around the 8-10p mark. So I am pondering that, at last, there is something positive he wishes to say and were the share price today around the 150p mark I would be really looking forward to next week. However the share price is 5p and very very good news is not about to make us longtermers rich or, I'm afraid, go anywhere near to recovering the substantial losses most have incurred. So I believe this webcast will be different/positive but I shall not be among those adding to my investment. I believe it will have something to do with Takeda. As a long shot I'll have a few quid on Cetilistat entering a phase I trial for the treatment of haemorrhoids. LOL Good luck all Regards PF
22/11/2008
21:09
kenilworth castle: VOW you know absolutley nothing with any certainty about where the share price will or will not go. You do not even know the terms of the expected rest of world deal for Cetilistat let alone to be in a position to make predictions about the subsequent share price. Infact you have in the last 6 or 7 weeks said (in this order) the price would go to 38p on technicals, then a takeover would be no more than 19p, and then you expected a slow rise to around 50p. You certainly are not consistent and have no credible track record as far as I can see to preach about the share price (feels more like shoving it down peoples throats). And you do not know anything about Alizymes deal negotiations. If you no longer hold as you just said then please do not post as you are not contributing anything useful. Some of us are able to do our own research and make our own minds up! If Cetilistat gets marketing approval in either Japan, North America or Europe, the share price will be very much higher - and more when sales build, or if ColalPred or ATL104 progress. That is what is for play here. If it is possible to buy stock sub 10p sub 5p or even 1p short term and then wait, so much the better because more profit will be made later on. Good post West Coast - 21576. Good points about Cetilistat and ColalPred being progressed at no further cost to Alizyme.
09/11/2008
18:19
dunderheed: Two good articles neither one mention of azm drug sadly. The reasons for my buying azm remain the same - however still am bemused why the share price is so low. Once again - can only assume it is because market does not like Timmy or his style of management. Feel even with a big Ceti deal the shares will still be significantly lower than 'true' value - for this very same reason. Thus would really like to see Timmy go - even if he delivers 'good' deal and the share price does not significantly recover after this. Feel a good deal will not significantly redeem him unless of course the share price shoots up!!
Alizyme share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161208 06:02:14